ArticleMolecular medicine reports2019
NLRP3 inflammasome inactivation driven by miR‑223‑3p reduces tumor growth and increases anticancer immunity in breast cancer.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- The Association Between miRNA-223-3p Levels and Pain Severity in Fibromyalgia Syndrome: A Molecular Approach.International journal of molecular sciences · 2025Article
- Investigation of the mechanism by which miR-223-3p inhibits reflux esophagitis through targeting the NLRP3 inflammasome.BMC gastroenterology · 2025Article
- NLRP3 promotes the proliferation and metastasis of colorectal cancer by regulating the S6K1-GLI1 signaling pathway.Journal of Cancer · 2025Article
- Molecular insights into NLRP3 inflammasome and miRNA modulation in oral cancer.Frontiers in pharmacology · 2025Review
- Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024Review
- MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.International journal of molecular sciences · 2024Review
- PANoptosis: a potential new target for programmed cell death in breast cancer treatment and prognosis.Apoptosis : an international journal on programmed cell death · 2024Review
- Implications of NLRP3 Suppression Using Glibenclamide and miR-223 against Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Epigenetic modifications in obesity-associated diseases.MedComm · 2024Review
- A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.BMC cancer · 2023Article
- Thymoquinone, a Novel Multi-Strike Inhibitor of Pro-Tumorigenic Breast Cancer (BC) Markers: CALR, NLRP3 Pathway and sPD-L1 in PBMCs of HR+ and TNBC Patients.International journal of molecular sciences · 2023Article
- Possible therapeutic targets for NLRP3 inflammasome-induced breast cancer.Discover oncology · 2023Review
- Blocking the Hormone Receptors Modulates NLRP3 in LPS-Primed Breast Cancer Cells.International journal of molecular sciences · 2023Article
- Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy.International journal of molecular sciences · 2023Review
- Research on the effect of interfering with miRNA-155 on triple-negative breast cancer cells.Genes & genomics · 2022Article
- miR-223-3p targets FBXW7 to promote epithelial-mesenchymal transition and metastasis in breast cancer.Thoracic cancer · 2022Article
- miR-223-3p Regulates NLRP3 to Inhibit Proliferation and Promote Apoptosis of ONG Cells.Computational and mathematical methods in medicine · 2022Article
- NLRP3 Inflammasome Activation: A Therapeutic Target for Cerebral Ischemia-Reperfusion Injury.Frontiers in molecular neuroscience · 2022Review
- The role of pyroptosis and its crosstalk with immune therapy in breast cancer.Frontiers in immunology · 2022Review
- Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.International journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA‑233‑3p (miR‑223‑3p) is considered an important cancer‑associated marker. The NACHT, LRR and PYD domains‑containing protein 3 (NLRP3) inflammasome represents a novel potential target for the treatment of breast cancer. Therefore, it was hypothesized that miR‑223‑3p may affect tumor growth and immunosuppression in breast cancer by inhibiting the NLRP3 inflammasome. In the present study, an increased expression level of NLRP3 was detected in three breast cancer cell lines compared with normal mammary epithelial cells (HMEC). Suppressing the expression of NLRP3 in MCF‑7 cell lines increased the apoptotic rate of breast cancer cells and reduced the proliferative capacity. NLRP3 was identified to be a direct target of miR‑233‑3p using a luciferase assay. In addition, miR‑233‑3p mimics inhibited the NLRP3‑dependent processes in cancer cells by suppressing the NLRP3 expression level and the protein expression levels of its downstream factors, including PYD and CARD domain containing protein, interleukin‑1β and interleukin‑18. In vivo experiments demonstrated the suppressive effect of miR‑233‑3p in tumor growth and immunosuppression. Collectively these findings suggested that the inactivation of the NLRP3 inflammasome driven by miR‑223‑3p reduced the growth and immunosuppression of breast cancer in vitro and in vivo, and may represent a novel therapeutic strategy in treating breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.